Clinical Trials
88 trialsNCT03520686 2026-05-26
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT04187404 2026-01-30
Spencer
Enterome
Phase 1/2 Terminated
NCT05002569 2026-01-08
RELATIVITY-098
Bristol-Myers Squibb
Phase 3 Terminated
NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT04935229 2025-10-22
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
TriSalus Life Sciences, Inc.
Phase 1 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT05350501 2025-09-29
CLAUDE
Enterome
Phase 2 Terminated
NCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT04149574 2025-09-16
CheckMate 7G8
Bristol-Myers Squibb
Phase 3 Terminated
NCT04278144 2025-09-15
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT04695977 2025-09-05
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2/3 Terminated
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT06191796 2025-06-12
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Exelixis
Phase 1 Terminated
NCT04698187 2025-06-11
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT06421311 2025-06-05
URADJ
Bristol-Myers Squibb
Terminated
NCT06535009 2025-06-04
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Ono Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT03110107 2025-04-24
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT06094296 2025-04-16
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT05543629 2025-03-18
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03371381 2025-02-04
An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
Janssen Research & Development, LLC
Phase 1/2 Terminated
NCT05375084 2024-12-12
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Navire Pharma Inc., a BridgeBio company
Phase 1 Terminated
NCT02702492 2024-11-25
PANAMA
Karyopharm Therapeutics Inc
Phase 1 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT03518320 2024-08-27
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Taris Biomedical LLC
Phase 1 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT05583188 2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4 Terminated
NCT04319224 2024-05-30
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Jounce Therapeutics, Inc.
Phase 1/2 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT02635061 2024-05-07
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Celgene
Phase 1 Terminated
NCT02954991 2024-04-22
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT05581719 2024-04-17
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Enlivex Therapeutics RDO Ltd.
Phase 1/2 Terminated
NCT04659369 2024-04-09
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 1 Terminated
NCT02723006 2024-03-05
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Takeda
Phase 1 Terminated
NCT04892043 2024-02-23
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Terminated
NCT03138499 2024-01-10
CheckMate 812
Bristol-Myers Squibb
Phase 3 Terminated
NCT04300140 2023-10-30
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
Phase 1/2 Terminated
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03606174 2023-08-24
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT03824704 2023-06-12
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Phase 2 Terminated
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT02054520 2023-04-18
Immunotherapy Study for Patients With Stage IV Melanoma
Lumos Pharma
Phase 2 Terminated